Pemetrexed Injection, Powder, Lyophilized, For Solution
Product Images NDC 68001-538

Product Visual Gallery

This gallery contains 14 technical images submitted to the FDA as part of the official labeling for Pemetrexed (NDC 68001-538). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Bluepoint Laboratories, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Structural Formula (Pemetrexed 01)

Chemical structure diagram of Pemetrexed disodium showing its molecular configuration including sodium ions and water of hydration (2.5 H2O) as part of the structure.*

FDA Label Image

Figure 1 (Pemetrexed 02)

A Kaplan-Meier survival curve chart showing overall survival percentage over time in months. Two treatment arms are compared: P+P+C (Pemetrexed for injection + pembrolizumab + platinum chemotherapy) represented by a black line and P+C (Pemetrexed for injection + platinum chemotherapy + placebo) represented by a gray line. The graph includes number at risk data for both groups at multiple time points up to 21 months.*

FDA Label Image

Figure 2 (Pemetrexed 03)

A Kaplan-Meier survival curve comparing survival probability over 30 months for two treatment groups: Pemetrexed plus Cisplatin (PC) shown with a solid line and Gemcitabine plus Cisplatin (GC) with a dotted line. The chart includes patient counts at risk for each group at multiple time points along the x-axis labeled 'Survival Time (months)' with y-axis labeled 'Survival Probability.'*

FDA Label Image

Figure 3 (Pemetrexed 04)

A Kaplan-Meier survival curve chart comparing survival probability over time (in months) for two treatment groups: Pemetrexed plus Cisplatin (PC) and Gemcitabine plus Cisplatin (GC). The chart includes a table indicating the number of patients at risk for each group at specified time intervals up to 30 months.*

FDA Label Image

Figure 4 (Pemetrexed 05)

A survival probability curve chart comparing Pemetrexed plus Cisplatin (solid line) and Gemcitabine plus Cisplatin (dotted line) treatments over a survival time of up to 30 months. The y-axis represents survival probability, and the x-axis represents time in months. Patient risk counts for each treatment group at multiple time points are shown below the graph.*

FDA Label Image

Figure 5 (Pemetrexed 06)

A Kaplan-Meier survival curve comparing survival probability over time (months) between Pemetrexed and placebo groups. The graph shows survival probability on the vertical axis and survival time in months on the horizontal axis, with two distinct lines representing Pemetrexed (solid) and placebo (dotted). Below the graph, a table lists the number of patients at risk at various time points for each group.*

FDA Label Image

Figure 6 (Pemetrexed 07)

A Kaplan-Meier survival curve chart depicting survival probability over time (months) comparing Pemetrexed injection with placebo. The solid line represents Pemetrexed, and the dotted line represents placebo. The x-axis shows survival time in months, and the y-axis shows survival probability. Below the graph is a table of patients at risk over the months for both groups.*

FDA Label Image

Figure 7 (Pemetrexed 08)

Survival probability curve for Pemetrexed compared with placebo over survival time in months. The solid line represents Pemetrexed, and the dotted line represents placebo, with patient risk numbers noted below the X-axis at intervals.*

FDA Label Image

Figure 8 (Pemetrexed 09)

A Kaplan-Meier survival curve comparing survival probability over time (in months) for patients treated with Pemetrexed versus placebo. The graph shows survival probability on the vertical axis and survival time in months on the horizontal axis, with two lines representing Pemetrexed and placebo groups. Below the graph is a table listing the number of patients at risk at various time points for each group.*

FDA Label Image

Figure 9 (Pemetrexed 10)

A survival probability chart comparing Pemetrexed plus Cisplatin versus Cisplatin alone over a 30-month period. The solid line represents Pemetrexed with Cisplatin, showing higher survival probability. The dotted line represents Cisplatin alone. The x-axis indicates survival time in months, and the y-axis indicates survival probability. Below the graph, a table shows the number of patients at risk at various time points for each treatment group.*

FDA Label Image

Vial Label-pemetrexed For Injection 100 mg Single-dose Vial (Pemetrexed 11)

Label for Pemetrexed for Injection, USP 100 mg per vial, an intravenous cytotoxic agent supplied as a single-dose vial. The label includes usage caution and storage instructions. It is manufactured by Olil Pharmaceutical (Hainan) Co., Ltd and labeled by BluePoint Laboratories.*

FDA Label Image

Package Carton- Pemetrexed For Injection 100 mg Single-dose Vial (Pemetrexed 12)

Packaging label for Pemetrexed for Injection, USP 100 mg/vial by BluePoint Laboratories. The label states it is for intravenous use only and is a single-dose vial. It includes reconstitution instructions and storage conditions, indicating the powder should be stored at 25°C with allowed excursions. The label also cautions that it is a cytotoxic agent and provides manufacturer information for Qilu Pharmaceutical (Hainan) Co., Ltd.*

FDA Label Image

Vial Label: Pemetrexed For Injection 500 mg Single-dose Vial (Pemetrexed 14)

Label for Pemetrexed for Injection, USP 500 mg per vial, a lyophilized powder for intravenous use. The label indicates it is a cytotoxic agent in a single-dose vial. Manufactured by Qilu Pharmaceutical (Hainan) Co., Ltd. for BluePoint Laboratories, with storage instructions and NDC 68001-539-41 shown.*

FDA Label Image

Package Carton: Pemetrexed For Injection 500 mg Single Dose Vial (Pemetrexed 15)

Packaging label for Pemetrexed for Injection, USP, 500 mg per vial, a single-dose vial powder lyophilized for intravenous injection. The label includes instructions for reconstitution and storage, cautions about cytotoxicity, and is manufactured by BluePoint Laboratories. The label also displays an NDC number 68001-539-41 and barcode.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.